	Application No.	Applicant(s)
Notice of Allowability	09/763,607	STAHLER ET AL.
	Examiner	Art Unit
	CHRISTOPHER M. GROSS	1639
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313 1. This communication is responsive to 28 December 2009.	(OR REMAINS) CLOSED in this a or other appropriate communication IGHTS. This application is subject	application. If not included on will be mailed in due course. THIS
2. X The allowed claim(s) is/are 2-11,18,21,27,37-41,44-50,57	and 58.	
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application No.	
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which give	IENT of this application. itted. Note the attached EXAMINE	R'S AMENDMENT or NOTICE OF
5. CORRECTED DRAWINGS (as "replacement sheets") mus	et ha submitted	
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		o o rey allastroa
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 6/30/2003 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	9.	ry (PTO-413), Pate <u>1/15/2010</u> . dment/Comment ment of Reasons for Allowance
	/ Christopher S. F. L Supervisory Patent E	ow / xaminer, Art Unit 1639

DETAILED ACTION

Status of the Application

Receipt is acknowledged of a responsive supplemental amendment, which was dated on 28 December 2009.

Status of the Claims

Claims 1-11,13-18,21-23,27-52, 56-57 were pending. Applicants canceled claims 1,13-17,22-23, 28-36, 42-43,51-56. In addition, Applicants amended claim 58. Therefore, claims 2-11,18,21,27,37-41,44-50,57-58 are currently pending and examined on the merits.

Please note that all previous species elections are hereby withdrawn in view of the fact that that the art search was extended to all species and no prior art was found that anticipates or renders obvious the instant claims in accordance with MPEP § 803.02. In view of the above noted withdrawal of the restriction requirement as to the linked species, applicant(s) are advised that if any claim(s) depending from or including all the limitations of the allowable generic linking claim(s) be presented in a continuation or divisional application, such claims may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no

Application/Control Number: 09/763,607 Page 3

Art Unit: 1639

longer applicable. See In re Ziegler, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Specification

The specification is objected to in accordance with 37 CFR 1.77(c) which requires section headings as follows:

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.
 - (1) Field of the Invention.
 - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF -HE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (I) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

Application/Control Number: 09/763,607 Page 4

Art Unit: 1639

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Please add the following as the first paragraph of the specification:

This application is a 371 of PCT/EP99/06316.

Authorization for this examiner's amendment was given in a telephone interview with Martha Cassidy on 1/15/2010 (see attached interview summary).

Please amend claim 58b as follows:

(b) positioning a transparent biochip carrier, wherein said carrier has a surface that comprises photoactivatable <u>cleavable protective</u> groups located thereon in <u>for photochemical synthesis at predetermined areas of said biochip carrier surface, between said illumination matrix and said detection matrix and in the light path of said illumination matrix such that light from the illumination matrix illuminates and is transmitted through said biochip carrier and to said detection matrix;</u>

Please amend claims 27 and 41 as follows:

- 27. (Currently Amended) The method of claim 58.
- (a) wherein said biochip carrier has a surface which comprises the photoactivatable cleavable protective groups located at en predetermined areas of said biochip carrier surface and wherein said programmable illumination matrix is a UV light source array comprising a plurality of individually controllable light sources; and
- (b) wherein said specific two-dimensional light exposure pattern activates said photoactivatable <u>cleavable protective</u> groups on <u>at</u> said selected predetermined area areas of said biochip carrier surface.
- 41. (Currently Amended) The method of claim 27, wherein said activating photoactivatable <u>cleavable protective</u> groups comprises cleaving a protective group on the

Application/Control Number: 09/763,607 Page 5

Art Unit: 1639

photoactivatable ,qroups on <u>at</u> said selected predetermined areas of said biochip carrier surface.

Allowable Subject Matter

Claims 2-11,18,21,27,37-41,44-50,57-58 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER M. GROSS whose telephone number is (571)272-4446. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571 272 0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christopher M Gross Examiner Art Unit 1639

cg